Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Inclusion Criteria: * Histologically proven diagnosis of glioblastoma or gliosarcoma (World Health Organization \[WHO\] grade IV) obtained at the time of a partial or gross total resection of the tumor. Patients who undergo a stereotactic needle biopsy alone are not eligible. * The tumor must have a supratentorial component. * History/physical examination within 14 days prior to enrollment. * The patient must have recovered from the effects of surgery, postoperative infection, and other complications before enrollment * Patient planning to receive brain RT, and concurrent and adjuvant temozolomide chemotherapy for six weeks as per standard of care therapy. Use of the Optune® (also known as Tumor Treating Fields or TTFields) device is allowed at provider discretion, but must begin after the Month 1 Post RT (10 week \[wk\]) Neurocognitive-PRO assessment. * Study drug (Ramipril) must be given \>= 21 days and ≤ 42 days after surgery. * All available brain magnetic resonance imaging (MRI) or computed tomography (CT) imaging reports from surgery to study completion must be submitted. This includes any post-operative or pre-radiation scan reports. * Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2 * Absolute neutrophil count (ANC) \>= 1,500 cells/mm\^3 (obtained within 14 days prior to enrollment) * Platelets \>= 100,000 cells/mm\^3 (obtained within 14 days prior to enrollment) * Hemoglobin \>= 10.0 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \…